This company has been acquired
AMAM Stock Overview
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Ambrx Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.00 |
| 52 Week High | US$28.15 |
| 52 Week Low | US$6.55 |
| Beta | 0 |
| 1 Month Change | 0.79% |
| 3 Month Change | 121.34% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 104.83% |
Recent News & Updates
Shareholder Returns
| AMAM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 3.7% | 1.2% |
| 1Y | n/a | -1.0% | 23.7% |
Return vs Industry: Insufficient data to determine how AMAM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AMAM performed against the US Market.
Price Volatility
| AMAM volatility | |
|---|---|
| AMAM Average Weekly Movement | 29.5% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMAM's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AMAM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 87 | Dan O'Connor | ambrx.com |
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology.
Ambrx Biopharma Inc. Fundamentals Summary
| AMAM fundamental statistics | |
|---|---|
| Market cap | US$1.77b |
| Earnings (TTM) | -US$67.06m |
| Revenue (TTM) | US$4.09m |
433.4x
P/S Ratio-26.5x
P/E RatioIs AMAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMAM income statement (TTM) | |
|---|---|
| Revenue | US$4.09m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.09m |
| Other Expenses | US$71.15m |
| Earnings | -US$67.06m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,638.31% |
| Debt/Equity Ratio | 0% |
How did AMAM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/06 17:20 |
| End of Day Share Price | 2024/03/06 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ambrx Biopharma Inc. is covered by 7 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |
| Louise Chen | Cantor Fitzgerald & Co. |